Biomarin Pharmaceutical Inc. (BMRN)
NASDAQ
Closed
Aug 21, 2026
Day's Range
66.5252 wk Range
49.26Overview - BMRN - Biomarin Pharmaceutical Inc.
Key Statistics
Valuation
Enterprise Value
16.42B
P/E (Trailing)
‪180.16‬
P/E (Forward)
‪10.29‬
PEG Ratio
‪-2.20‬
Price / Sales (TTM)
‪3.78‬
Price / Book
‪2.04‬
EV / EBITDA
‪25.45‬
Profitability
Gross Margin
‪79.50%‬
Profit Margin
‪2.14%‬
Operating Margin
‪21.16%‬
Return on Assets
‪3.25%‬
Return on Equity
‪1.18%‬
Ownership
Shares Outstanding
193.28M
Float
192.39M
Short % of Shares Outstanding
‪6.48%‬
Held by Insiders
‪0.34%‬
Held by Institutions
‪103.75%‬
Price stats
Beta
‪0.22‬
50-Day Avg
‪60.41‬
200-Day Avg
‪57.17‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
25 analysts
Average price target
‪$ 90.32‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BMRN - Biomarin Pharmaceutical Inc.
Peers - BMRN - Biomarin Pharmaceutical Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.16P/E (Trailing)‪2.14%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- ARWRNASDAQArrowhead Pharmaceuticals Inc.12.30BMarket Cap+76.22%52-week change47.10P/E (Trailing)‪-47.79%‬Profit Margin
Profile Summary - BMRN - Biomarin Pharmaceutical Inc.
About
BioMarin Pharmaceutical Inc. is a leading global biotechnology company specializing in the development and commercialization of therapies for people with serious and life-threatening rare genetic diseases. Its portfolio includes eight approved treatments targeting conditions such as mucopolysaccharidosis types I, IVA,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
